Clinical Trials Logo

Clinical Trial Summary

Fluid-unresponsive hypotension needing cardiotropic drug treatment is a serious complication in very preterm neonates with suspected late-onset sepsis (LOS; defined as culture positive or negative bloodstream infection or necrotizing enterocolitis occurring >48 hours of age). In Canada, ~250 very preterm neonates receive cardiotropic drugs for LOS related fluid-unresponsive hypotension every year; of these ~35-40% die. Unlike for adult patients, there is little evidence to inform practice. While several medications are used by clinicians, the most frequently used medications are Dopamine (DA) and Norepinephrine (NE). However, their relative impact on patient outcomes and safety is not known resulting in significant uncertainty and inter- and intra-unit variability in practice. Conducting large randomized trials in this subpopulation can be operationally challenging and expensive. Comparative effectiveness research (CER), is a feasible alternative which can generate high-quality real-world evidence using real-world data, by comparing the impact of different clinical practices. Aim: To conduct an international CER study, using a pragmatic clinical trial design, in conjunction with the existing infrastructure of the Canadian Neonatal Network to identify the optimal management of hypotension in very preterm neonates with suspected LOS. Objective: To compare the relative effectiveness and safety of pharmacologically equivalent dosages of DA versus NE for primary pharmacotherapy for fluid-unresponsive hypotension in preterm infants born ≤ 32 weeks gestational age with suspected LOS. Hypothesis: Primary treatment with NE will be associated with a lower mortality Methods: This CER project will compare management approach at the unit-level allowing inclusion of all eligible patients admitted during the study period. 15 centers in Canada, 4 centers in Ireland, 2 centers in Israel and 6 centers in the United States have agreed to standardize their practice. All eligible patients deemed circulatory insufficient will receive fluid therapy (minimum 10-20 cc/kg). If hypotension remains unresolved: Dopamine Units: start at 5mics/kg/min, increase every 16-30 minutes by 5 mics/kg/min to a maximum dose of 15 mics/kg/min or adequate response Norepinephrine Units: start at 0.05 mics/kg/min, increase every 16-30 minutes by 0.05 mics/kg/min to maximum dose of 0.15/mics/kg/min or adequate response


Clinical Trial Description

In this study, we will use real world data (RWD; defined as data generated during routine clinical practice) collected by our national Canadian Neonatal Network (CNN), which will be further expanded for this project. The CNN is a well-established patient registry that includes members from 31 hospitals and 17 universities across Canada. The Network maintains a standardized NICU database and provides a unique opportunity for researchers to participate in collaborative projects. We will use the framework of Hypotheses Evaluating Treatment Effectiveness (HETE) research a form of comparative effectiveness research (CER). Patient registries are emerging as a new method for assessment of treatments under the framework of CER. We will evaluate treatment effectiveness of two routinely used primary therapies for hypotension management in very preterm neonates with suspected LOS after standardizing treatment strategies and with a priori hypothesis. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05347238
Study type Observational [Patient Registry]
Source Mount Sinai Hospital, Canada
Contact Amish Jain, MBBS, MRCPCH, PhD
Phone 416-586-4800
Email amish.jain@sinaihealth.ca
Status Recruiting
Phase
Start date February 6, 2023
Completion date March 31, 2027

See also
  Status Clinical Trial Phase
Recruiting NCT05134116 - SafeBoosC III Two-year Follow-up
Active, not recruiting NCT03714633 - Stockholm Preterm Interaction-Based Intervention N/A
Not yet recruiting NCT05490173 - The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants N/A
Active, not recruiting NCT04459117 - Prophylactic Treatment of the Ductus Arteriosus in Preterm Infants by Acetaminophen Phase 2/Phase 3
Completed NCT03649282 - HFNC and NCPAP in Extremely Preterm Infants N/A
Completed NCT01773902 - Protein for Premies N/A
Completed NCT04121897 - Therapist Education and Massage for Parent Infant-Outcomes N/A
Recruiting NCT04413097 - Delayed Cord Clamping With Oxygen In Extremely Low Gestation Infants N/A
Recruiting NCT05265195 - PeriviAble DeLiveries: ALIgning PArental aNd PhysiCian PrioritiEs (ALLIANCE)
Completed NCT05686252 - RCT: The Effect of Held Position During Kangaroo Care on Physiological Parameters of Premature Infants N/A
Recruiting NCT06027645 - Early Intervention Based on Neonatal Crawling in Very Premature Infants at Risk For Neurodevelopmental Disorder N/A
Completed NCT04074525 - Evaluating Decisional Regret Among Mothers
Completed NCT05152875 - Relationship Between Fungal Colonization and Severe Bronchopulmonary Dysplasia
Completed NCT02782637 - Prenatal Counseling in Extreme Prematurity: Parents' View N/A
Recruiting NCT04715373 - LISA in the Delivery Room for Extremely Preterm Infants N/A
Not yet recruiting NCT05334550 - Effectiveness of Home Based Early Intervention of Extremely Premature Infant by Parent N/A
Not yet recruiting NCT06220461 - Folic Acid Supplementation to Reduce Anemia in Extremely Preterm Infants N/A
Recruiting NCT05248477 - Improve the Survival Without Morbidity of Extremely Preterm Infants (PREMEX) N/A
Completed NCT04652063 - Osteopathic Manipulative Medicine to Reduce Developmental Delays N/A
Completed NCT04256889 - Use Of Nfant(R) Technology Feeding System For Infants Less Than 30 Weeks GA N/A